Adenocarcinoma emerged as the only statistically significant favorable prognostic factor, reflecting its intrinsically slower growth kinetics and the availability of multiple genotype‐matched targeted agents (EGFR, ALK, ROS1, and RET inhibitors), which enable effective sequential treatment following recurrence and thereby may extend OS. This evidence concerns the gene EGFR and adenocarcinoma.